Intravenous Autologous Adipose‑Derived Expanded Mesenchymal Stem Cell Therapy in Inclusion Body Myositis: A First‑in‑Human Case Report
Advances in Orthopedics and Sports Medicine · 2026 · 01 (01)
DOI: 10.37722/aoasm.2026101 ↗Kurz gefasst
Fallbericht in der Zeitschrift Advances in Orthopedics and Sports Medicine, 2026. Verfasst von Hassan Mubark. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Inclusion body myositis (IBM) is the most common acquired inflammatory myopathy in individuals over 50 years of age and remains refractory to conventional immunosuppressive and disease-modifying therapies. Its pathogenesis reflects a multifactorial process involving chronic cytotoxic T-cell–mediated inflammation, protein dyshomeostasis, mitochondrial dysfunction, and progressive muscle fiber degeneration. To date, human cell-based studies in IBM have been confined to localized intramuscular administration of adipose-derived mesenchymal stem cells, with no published reports describing systemic intravenous cell therapy.
Zitieren
APA
Mubark, H. (2026). Intravenous Autologous Adipose‑Derived Expanded Mesenchymal Stem Cell Therapy in Inclusion Body Myositis: A First‑in‑Human Case Report. Advances in Orthopedics and Sports Medicine, 01(01). https://doi.org/10.37722/aoasm.2026101
Vancouver
Mubark H. Intravenous Autologous Adipose‑Derived Expanded Mesenchymal Stem Cell Therapy in Inclusion Body Myositis: A First‑in‑Human Case Report. Advances in Orthopedics and Sports Medicine. 2026;01(01). doi:10.37722/aoasm.2026101
BibTeX
@article{Mubark2026,
author = {Mubark, Hassan},
title = {Intravenous Autologous Adipose‑Derived Expanded Mesenchymal Stem Cell Therapy in Inclusion Body Myositis: A First‑in‑Human Case Report},
journal = {Advances in Orthopedics and Sports Medicine},
year = {2026},
volume = {01},
number = {01},
doi = {10.37722/aoasm.2026101}
}
EUVIMED